Contract research organization Charles River Laboratories has signed agreements to sell several of its divisions. The European early-stage drug development assets (Discovery Services) will be transferred to IQVIA, while the contract manufacturing (CDMO) business will be acquired by the investment firm GI Partners.
Strategic Motives: Why IQVIA Needs Preclinical Assets
The transaction reflects the transformation of IQVIA’s business model. The company, historically specializing in healthcare data analytics and clinical trials (late phases), is expanding its presence in the earliest stages of drug creation.
The perimeter of the deal includes five European research sites, an artificial intelligence platform for small molecule discovery, and New Approach Methodologies (NAMs) for animal-free testing. These assets have direct synergy with IQVIA’s core analytical business:
- Charles River’s AI platform complements IQVIA’s big data competencies, allowing the direct application of machine learning algorithms to model new molecules.
- The acquisition allows IQVIA to offer pharmaceutical clients a continuous cycle of services: from molecule discovery and in vitro testing to clinical trials and drug commercialization.
Financial Parameters and Transaction Terms
The base value of the deal between Charles River and IQVIA is $145 million in cash, with the possibility of additional contingent payments of up to $10 million. The revenue of the acquired assets for 2025 was $144 million. Target therapeutic areas include oncology, neuroscience, immunology, and orphan diseases.
The second agreement involves the sale of the CDMO and Cell Solutions divisions (manufacturing facilities in the US and the UK) to the investment company GI Partners. The structure of this transaction provides for contingent performance-based payments tied to the future financial results of the assets. The total revenue of these divisions in 2025 was $143 million.
Implications for Charles River Laboratories
The divestiture of these divisions is part of Charles River’s portfolio optimization. The sale of non-core assets will lead to a decrease in the company’s reported revenue in 2026 by more than $200 million. At the same time, the restructuring will ensure an increase in the non-GAAP operating margin by at least 100 basis points, which allowed the company to raise its annual adjusted profit forecast. Both transactions are expected to close in the second quarter of 2026.
Summary Parameters of Charles River Laboratories M&A Transactions
| Parameter | Value |
|---|---|
| Seller | Charles River Laboratories |
| Buyers | IQVIA Holdings Inc. and GI Partners |
| Transaction rationale for IQVIA | Integration of early development (AI, in vitro) with clinical expertise |
| IQVIA transaction value | $145 million in cash (+ up to $10 million in contingent payments) |
| Assets for IQVIA | 5 research sites in Europe (2025 revenue: $144 million) |
| GI Partners transaction terms | Contingent payments dependent on financial results |
| Assets for GI Partners | CDMO and Cell Solutions divisions (2025 revenue: $143 million) |
| Target closing date | Q2 2026 |
